Validated LC-MS/MS methodology for the quantification of CBD, trace level THCA and UK controlled cannabinoids (Δ-THC, Δ-THC, CBN and THCV) in food samples.

Products containing cannabidiol (CBD) have become increasingly popular due to consumer-perceived benefits of improving health and well-being. More specifically in the United Kingdom (UK), CBD food products are categorised as . For these products to remain on the market, they must have authorisation from the Food Standards Agency on the basis that they are safe, correctly labelled, and do not contain substances classified under controlled drugs legislation in accordance with any existing or future Home Office guidance.

Neurofilament Light Chain under the Lens of Structural Mass Spectrometry.

Neurofilament light chain (NfL) is an early nonspecific biomarker in neurodegenerative diseases and traumatic brain injury, indicating axonal damage. This work describes the detailed structural characterization of a selected primary calibrator with the potential to be used in future reference measurement procedure (RMP) development for the accurate quantification of NfL. As a part of the described workflow, the sequence, higher-order structure as well as solvent accessibility, and hydrogen-bonding profile were assessed under three different conditions in KPBS, artificial cerebrospinal fluid, and artificial cerebrospinal fluid in the presence of human serum albumin.

Revascularization in a Time After CORAL.

Revascularization of renal artery stenosis became less common following randomized controlled trials that failed to demonstrate benefit in low-risk patients. An 88-year-old patient with recurrent acute pulmonary edema and progressive kidney disease in the setting of high-grade renal artery stenosis, a phenotype excluded from these trials, underwent revascularization.

A candidate reference measurement procedure for the quantification of α-synuclein in cerebrospinal fluid using an SI traceable primary calibrator and multiple reaction monitoring.

α-synuclein aggregation is an important hallmark of neurodegenerative diseases such as Parkinson's disease (PD) and Lewy body dementia. α-synuclein has been increasingly used as a diagnostic biomarker in PD and other synucleinopathies. Current clinical assays rely on antibody-based immunoassays to detect α-synuclein, which possess high sensitivity, afford high throughput and require small sample volumes.

Glaucoma severity at first presentation to an ophthalmologist and risk factors for late presentation in rural Australia: the S1P study.

Clinical Relevance: Well-targeted referrals and timely commencement of treatment are essential to limiting vision loss in glaucoma. Optometrists, primary care providers, and public health policymakers can utilise predictors of late to identify and target at-risk populations.

Background: This study, which aimed to evaluate glaucoma severity at first presentation to an ophthalmologist in a rural Australian population, is the first of its kind in an Australian population.